These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2515605

  • 1. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates.
    Morfini M, Rafanelli D, Filimberti E, Cinotti S, Piazza E, Longo G, Rossi Ferrini P.
    Thromb Res; 1989 Oct 15; 56(2):169-78. PubMed ID: 2515605
    [Abstract] [Full Text] [Related]

  • 2. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
    Thomas KB, McGrath KM, Taylor M, Young IF, Herrington RW, Schiff P.
    Transfusion; 1988 Oct 15; 28(1):8-13. PubMed ID: 3124306
    [Abstract] [Full Text] [Related]

  • 3. Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.
    Clifton JG, Huang F, Kovac S, Yang X, Hixson DC, Josic D.
    Electrophoresis; 2009 Oct 15; 30(20):3636-46. PubMed ID: 19768705
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunoaffinity purification of factor VIII complex.
    Hornsey VS, Griffin BD, Pepper DS, Micklem LR, Prowse CV.
    Thromb Haemost; 1987 Feb 03; 57(1):102-5. PubMed ID: 3109055
    [Abstract] [Full Text] [Related]

  • 6. Immunoaffinity purification of factor VIII.
    Weinstein RE.
    Ann Clin Lab Sci; 1989 Feb 03; 19(2):84-91. PubMed ID: 2502062
    [Abstract] [Full Text] [Related]

  • 7. High-purity factor VIII concentrates produced without using monoclonal antibodies.
    Mannucci PM, Gringeri A, Cattaneo M.
    Ric Clin Lab; 1990 Feb 03; 20(4):227-37. PubMed ID: 2127470
    [Abstract] [Full Text] [Related]

  • 8. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
    Lin Y, Yang X, Chevrier MC, Craven S, Barrowcliffe TW, Lemieux R, Ofosu FA.
    Haemophilia; 2004 Sep 03; 10(5):459-69. PubMed ID: 15357771
    [Abstract] [Full Text] [Related]

  • 9. In vitro characterization of various factor VIII concentrates.
    Yoshioka A, Shima M, Nishino M, Yoshikawa N, Fukui H.
    Arzneimittelforschung; 1987 Jul 03; 37(7):753-6. PubMed ID: 3118888
    [Abstract] [Full Text] [Related]

  • 10. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G, Carretero M, Magallón M, Quintana M, Arnau C, Castillo R, Aznar-Salatti J.
    Haematologica; 1998 Nov 03; 83(11):1009-14. PubMed ID: 9864923
    [Abstract] [Full Text] [Related]

  • 11. Purification of the factor VIII complex.
    Thorell L, Blombäck B.
    Thromb Res; 1984 Aug 15; 35(4):431-50. PubMed ID: 6435279
    [Abstract] [Full Text] [Related]

  • 12. Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.
    Brettler DB, Forsberg AD, Levine PH, Petillo J, Lamon K, Sullivan JL.
    Blood; 1989 May 15; 73(7):1859-63. PubMed ID: 2496775
    [Abstract] [Full Text] [Related]

  • 13. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE, Smith JK.
    Thromb Haemost; 1982 Aug 24; 48(1):46-8. PubMed ID: 6813994
    [Abstract] [Full Text] [Related]

  • 14. Factor VIII concentrate: what is "high purity"?
    Schoppmann A, Weber A, Hondl F, Linnau Y.
    Thromb Haemost; 1994 Sep 24; 72(3):483-4. PubMed ID: 7855803
    [No Abstract] [Full Text] [Related]

  • 15. The role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation.
    Mazurier C, Samor B, Deromeuf C, Goudemand M.
    Thromb Res; 1985 Mar 15; 37(6):651-8. PubMed ID: 3922084
    [Abstract] [Full Text] [Related]

  • 16. [Comparative protein chemistry studies on Factor VIII concentrates].
    Kienast K, Trobisch H.
    Arzneimittelforschung; 1984 Mar 15; 34(8):895-900. PubMed ID: 6437415
    [Abstract] [Full Text] [Related]

  • 17. Factor VIII:C assay: influence of buffer components used in immunoaffinity chromatography for purification of factor VIII/von Willebrand factor.
    Koops K, Hoff HS, Heethuis A, Das PC, Smit Sibinga CT.
    Thromb Res; 1994 May 15; 74(4):347-54. PubMed ID: 8085236
    [Abstract] [Full Text] [Related]

  • 18. Cryoprecipitate and Factor VIII commercial concentrates: in vitro characteristics and in vivo compartmental analysis.
    Morfini M, Longo G, Matucci M, Vannini S, Messori A, Filimberti E, Duminuco M, Avanzi G, Rossi-Ferrini P.
    Ric Clin Lab; 1984 May 15; 14(4):681-91. PubMed ID: 6441235
    [Abstract] [Full Text] [Related]

  • 19. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV, Griffin B, Pepper DS, Dickson AJ, McQuillan TA, Dickson IH, Foster PR.
    Thromb Haemost; 1981 Oct 15; 46(3):597-601. PubMed ID: 6797090
    [Abstract] [Full Text] [Related]

  • 20. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM.
    Wien Klin Wochenschr; 1982 Oct 15; 94(19):509-14. PubMed ID: 6818773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.